Talphera announced the first patient has been enrolled in the NEPHRO CRRT study. The NEPHRO CRRT registrational study will enroll 166 patients undergoing continuous renal replacement therapy at up to 14 clinical sites across the United States. The primary endpoint of the study is the mean post-filter activated clotting time for circuits infused with nafamostat versus placebo over the first 24 hours.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLPH:
- Talphera price target lowered to $3.50 from $4.25 at Alliance Global Partners
- Talphera Announces CMO Retirement and Successor Appointment
- Talphera reports Q2 EPS (15c) vs. (41c) last year
- Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Talphera Shareholders Affirm Leadership and Financial Strategy